Last updated: September 3, 2026
Camostat mesylate is an oral serine protease inhibitor with established use in Japan for chronic pancreatitis and postoperative reflux esophagitis. Its COVID-19 development program did not produce clinical evidence of benefit, and the drug has no established FDA approval in the United States. The commercial outlook is therefore concentrated in Japan and other limited markets, with potential upside only if a new indication demonstrates clear clinical value.
What is camostat and how does it work?
Camostat mesylate inhibits several serine proteases, including trypsin, kallikrein, plasmin, and transmembrane serine protease 2, or TMPRSS2. The drug is rapidly converted to the active metabolite FOY-251, also known as 4-(4-guanidinobenzoyloxy)phenylacetic acid.
Camostat has been investigated in:
- Chronic pancreatitis
- Postoperative reflux esophagitis
- Acute pancreatitis
- COVID-19
- Pulmonary and inflammatory diseases
- Fibrotic disorders
- Viral entry inhibition
The COVID-19 rationale came from laboratory evidence that camostat could inhibit TMPRSS2-mediated SARS-CoV-2 entry into host cells. That mechanism did not translate into a demonstrated clinical benefit in randomized trials.
Who developed camostat?
Camostat was developed in Japan and marketed principally by Ono Pharmaceutical under the brand name Foipan. The original small-molecule composition is an older compound, meaning that commercial protection is more likely to depend on regulatory approvals, formulation rights, manufacturing know-how, and indication-specific intellectual property than on broad composition-of-matter exclusivity.
What is the regulatory status of camostat?
Camostat mesylate is approved in Japan for chronic pancreatitis and postoperative reflux esophagitis. It is not approved by the U.S. Food and Drug Administration for any indication based on the public regulatory record available through June 2024.
| Jurisdiction |
Regulatory status |
Primary use or development |
| Japan |
Approved |
Chronic pancreatitis and postoperative reflux esophagitis |
| United States |
Not FDA-approved |
Investigational use |
| European Union |
No centralized approval identified |
Clinical research, including COVID-19 studies |
| Australia |
Investigational COVID-19 use studied |
Randomized clinical research |
| United Kingdom |
Investigational COVID-19 use studied |
National platform trial |
| China |
Development and research activity reported |
No broad global approval equivalent to Japan established |
The Japanese approval gives camostat a commercial base, but the product is not positioned as a global specialty pharmaceutical with broad regulatory exclusivity.
What clinical development has camostat completed?
Chronic pancreatitis and postoperative reflux
Camostat has long been used in Japan as a treatment for symptoms associated with chronic pancreatitis and postoperative reflux esophagitis. The product’s established use is primarily regional and genericized.
Its clinical value in chronic pancreatitis is linked to suppression of pancreatic protease activity. The product does not eliminate the major structural and metabolic causes of chronic pancreatitis, and treatment remains part of a broader management strategy.
COVID-19 development
Camostat entered multiple COVID-19 studies after in vitro research identified TMPRSS2 inhibition as a possible method of reducing SARS-CoV-2 cell entry.
Key results included:
| Study or evidence source |
Design |
Result |
| Hoffmann et al. |
In vitro SARS-CoV-2 entry study |
Camostat inhibited TMPRSS2-dependent viral entry in cell models [1] |
| CamoSARS-CoV-2 trial |
Randomized clinical study in hospitalized patients |
No meaningful improvement in clinical outcomes; trial stopped for futility [2] |
| ACTIV-2 |
Randomized outpatient platform study |
Camostat did not show a clinically meaningful benefit in the studied population [3] |
| PRINCIPLE |
Community-based randomized platform trial |
No sufficient evidence to support routine use for recovery or hospitalization reduction [4] |
| Australian and other randomized studies |
Hospitalized or outpatient populations |
No consistent efficacy signal established |
The program was weakened by several factors:
- Camostat is rapidly hydrolyzed, limiting sustained systemic exposure.
- TMPRSS2 dependence varies by viral variant and tissue.
- Omicron-lineage viruses rely less on TMPRSS2 than earlier variants in some experimental systems.
- Treatment in hospitalized patients may occur after the principal viral replication phase.
- The product’s pharmacokinetics may not achieve sufficient airway or tissue exposure at conventional oral doses.
The development record does not support a COVID-19 commercial relaunch without new formulation, dosing, or patient-selection evidence.
When did camostat lose exclusivity?
The original camostat compound is decades old, and broad composition-of-matter exclusivity is not a current commercial barrier. The exact expiration history of the original Japanese patents is not the primary determinant of present market access.
Current protection is more likely to arise from:
- Country-specific formulation patents
- Extended-release or targeted-delivery systems
- Combination products
- New therapeutic indications
- Dosing regimens
- Inhaled or pulmonary delivery
- Manufacturing processes
- Regulatory exclusivity for a newly approved indication
No broad, globally controlling patent estate has been established publicly for camostat comparable to the patent portfolios surrounding newer specialty medicines.
What patents protect camostat?
The active ingredient is an old small molecule. Publicly available records include historic Japanese and international filings associated with camostat synthesis and pharmaceutical use, but these legacy rights are generally expected to have expired or to be commercially immaterial.
The more relevant patent question is whether a sponsor has secured enforceable rights around a new product configuration. Potential areas include:
| Protection category |
Commercial relevance |
| Composition of matter |
Low for the original camostat molecule because of age |
| Salt or crystal form |
Potentially relevant if a novel, non-obvious form is claimed |
| Oral formulation |
Moderate if improved stability, absorption, or dosing is demonstrated |
| Inhaled formulation |
Potentially significant for respiratory indications |
| Method of treatment |
Relevant for a new disease or biomarker-defined population |
| Combination therapy |
Relevant if clinical benefit depends on another antiviral or anti-inflammatory agent |
| Manufacturing process |
Relevant where process impurities or yield create a meaningful cost advantage |
A camostat program based only on the old oral product would face limited patent protection and rapid generic competition. A program using a proprietary pulmonary formulation could present a stronger, although still contestable, patent position.
What is the Orange Book status of camostat?
Camostat does not have an FDA-approved reference product listed in the U.S. Orange Book based on the public record through June 2024. There is therefore no established U.S. Orange Book patent listing, FDA reference-listed drug, or conventional Abbreviated New Drug Application pathway tied to an approved U.S. camostat product.
If a sponsor seeks U.S. approval, the likely regulatory route would depend on the proposed indication and product development strategy:
- A 505(b)(2) application could be considered for a reformulated or repurposed product.
- A new drug application could be required for a novel clinical indication or delivery system.
- An ANDA would require an FDA-approved reference product, which is not currently established for camostat in the United States.
A 505(b)(2) strategy could reduce development requirements if the sponsor can rely on prior findings for camostat or related products. It would not remove the need to establish efficacy, safety, product quality, and an appropriate dosage form for the proposed U.S. indication.
Are there Paragraph IV challenges or generic entry risks?
No major U.S. Paragraph IV litigation campaign is associated with camostat because there is no established FDA-approved camostat reference product with a conventional Orange Book patent estate.
Generic entry risk differs by jurisdiction:
| Market |
Generic entry risk |
Reason |
| Japan |
High |
Older approved product and established generic-drug environment |
| United States |
Not yet applicable in the conventional sense |
No FDA-approved reference product |
| Europe |
High if approval is pursued without new IP |
Old active ingredient and limited exclusivity |
| Emerging markets |
High |
Price competition and weak differentiation likely |
A new formulation could delay direct substitution through formulation or method-of-use patents. Those rights would face validity and enablement challenges because camostat has been studied for many years and the underlying mechanism is publicly documented.
How strong is the camostat patent estate?
The patent estate is weak for the legacy product and potentially moderate for a genuinely differentiated formulation.
Weaknesses
- Old active ingredient
- Extensive prior art
- No broad new-molecule exclusivity
- Limited evidence of durable clinical differentiation
- Generic manufacturing feasibility
- Failed or inconclusive COVID-19 efficacy program
Potential strengths
- New inhaled delivery technology
- Demonstrated improvement in lung exposure
- Validated biomarker-selected population
- Proprietary combination with a complementary antiviral
- New indication supported by controlled clinical data
- Manufacturing process that materially improves purity or cost
A sponsor cannot rely on TMPRSS2 inhibition alone to create a strong commercial moat. The mechanism is widely known, and patent claims directed broadly to treating viral infection with camostat would face substantial prior-art and obviousness exposure.
Which companies are challenging or competing with camostat?
Camostat competes with established therapies rather than with a single direct branded rival.
In chronic pancreatitis
Competition includes:
- Pancreatic enzyme replacement therapy
- Analgesics
- Endoscopic interventions
- Surgery
- Nutritional management
- Other symptom-directed medicines
Camostat’s role is geographically limited, and pancreatic enzyme replacement remains the more established treatment category in many markets.
In COVID-19
Camostat competed experimentally with:
- Nirmatrelvir/ritonavir
- Remdesivir
- Molnupiravir
- Neutralizing antibodies
- Other host-directed antiviral candidates
These competitors had stronger clinical or regulatory positions. Nirmatrelvir/ritonavir and remdesivir established the principal commercial benchmarks for early COVID-19 treatment, while camostat did not demonstrate comparable efficacy.
In respiratory and fibrotic diseases
Potential competitors include:
- Inhaled corticosteroids
- Antifibrotic medicines
- Direct-acting antivirals
- Protease inhibitors
- Biologic anti-inflammatory therapies
Camostat would need a clear benefit in a defined population to justify adoption against these treatments.
What licensing deals affect camostat?
Camostat development has involved academic collaborations, government-supported studies, and clinical research networks. The public record does not establish a major global licensing transaction that transferred a large commercial camostat franchise to a multinational pharmaceutical company.
The commercial structure is therefore different from products supported by large regional licensing agreements. Any future value would likely require:
- A sponsor with a proprietary formulation
- Regional rights obtained from an existing Japanese holder
- A 505(b)(2) development partnership
- A licensing arrangement around a new delivery platform
- An indication-specific collaboration with a respiratory or specialty pharmaceutical company
No widely disclosed transaction has demonstrated that camostat has been assigned a high strategic value by a major global pharmaceutical company.
What is the market projection for camostat through 2030?
The base-case outlook is a stable, low-growth regional market centered on Japan. The COVID-19 opportunity has largely closed because clinical trials did not confirm efficacy and the treatment environment has shifted toward approved direct-acting antivirals.
Base case
Camostat remains available in Japan for established indications, with revenue shaped by:
- Generic and price pressure
- Stable chronic pancreatitis demand
- Limited geographic expansion
- No major new indication
- No substantial premium for the legacy oral formulation
Under this case, the product is a mature niche medicine rather than a growth asset.
Upside case
The upside scenario requires a new clinical and intellectual-property proposition, such as:
- Inhaled camostat for a respiratory disorder
- A formulation that materially increases pulmonary exposure
- Use in a biomarker-defined TMPRSS2-dependent disease
- Combination therapy with a direct antiviral
- A non-COVID indication with a large untreated population
This scenario could support a specialty product with higher pricing, but it would require new phase 2 and phase 3 evidence, a defensible patent position, and regulatory approval.
Downside case
The downside scenario includes:
- Continued generic erosion in Japan
- Failure of new respiratory or fibrotic indications
- No U.S. or European approval
- Displacement by better-supported treatments
- Reduced research funding for host-directed antivirals
The probability of a large global camostat market appears low without a new product profile. The most realistic commercial projection is a mature, localized market with limited expansion potential.
What generic launch scenarios exist for camostat?
Scenario 1: Legacy oral generic
A generic manufacturer markets a conventional oral camostat product where local regulatory requirements permit. Competition is based primarily on price, supply reliability, and reimbursement access.
Scenario 2: U.S. repurposing through 505(b)(2)
A sponsor develops a new dosage form or indication. The product receives a period of regulatory exclusivity, but patent protection depends on the novelty and enforceability of the formulation or use claims.
Scenario 3: Inhaled product
A sponsor develops an inhaled camostat formulation. This could delay direct substitution because an inhaled product would not be therapeutically or pharmaceutically equivalent to the legacy oral product. The commercial opportunity would depend on demonstrated clinical benefit and device or formulation patents.
Scenario 4: Combination product
Camostat is combined with another antiviral or anti-inflammatory agent. This could support a new clinical proposition but would face combination-patent, clinical-design, and reimbursement barriers.
What manufacturing and intellectual-property barriers exist?
Camostat is a synthetic small molecule, not a biologic. Manufacturing barriers are therefore lower than for monoclonal antibodies, cell therapies, or complex peptides.
Key technical considerations include:
- Control of ester hydrolysis
- Impurity profile
- Stability of camostat mesylate
- Particle-size control
- Oral bioavailability
- Conversion to FOY-251
- Batch-to-batch consistency
- Protection from moisture and degradation
A conventional oral product is unlikely to have a strong manufacturing moat. An inhaled or modified-release product would create greater technical complexity, but the sponsor would need to show that the complexity produces meaningful clinical or pharmacokinetic advantages.
What patent litigation affects camostat?
No major U.S. patent litigation involving an Orange Book-listed camostat product is established in the public record through June 2024. The absence of litigation is consistent with the lack of an FDA-approved reference product and the age of the active ingredient.
Future disputes would most likely concern:
- Validity of formulation patents
- Obviousness of new dosing regimens
- Infringement by inhaled products
- Patent ownership arising from university-sponsored research
- Inventorship of new indications
- Regulatory reliance under a 505(b)(2) application
A litigation risk assessment for a new camostat product would need to focus on claim scope, prosecution history, written description, enablement, and the technical distinction between oral and pulmonary delivery.
How does camostat compare with established antiviral drugs?
| Attribute |
Camostat |
Nirmatrelvir/ritonavir |
Remdesivir |
| Drug type |
Host serine protease inhibitor |
Direct SARS-CoV-2 protease inhibitor |
Nucleotide analog antiviral |
| Oral availability |
Yes |
Yes |
No, intravenous |
| FDA COVID-19 approval |
No |
Yes |
Yes |
| Clinical COVID-19 efficacy |
Not established |
Established in high-risk patients |
Established in selected patients |
| Patent position |
Weak for legacy product |
Stronger, though time-limited |
Stronger, though time-limited |
| Main commercial market |
Japan, established indications |
Global COVID-19 treatment |
Global hospital and outpatient use |
| Future growth driver |
New formulation or indication |
Enduring antiviral demand and resistance management |
Intravenous use and expanded indications |
Camostat has a lower development and manufacturing burden than a new chemical entity, but it lacks the clinical validation and commercial exclusivity of approved antiviral competitors.
Key Takeaways
- Camostat mesylate is approved in Japan for chronic pancreatitis and postoperative reflux esophagitis.
- It has no established FDA approval or Orange Book listing in the United States.
- Randomized COVID-19 trials did not establish clinically meaningful efficacy.
- The original molecule is old, so composition-of-matter patent protection is not a current commercial advantage.
- A conventional oral camostat product has high generic and price-competition risk.
- The strongest future opportunity would involve an inhaled, targeted, or otherwise differentiated formulation.
- A large global market through 2030 is unlikely without new clinical evidence and new intellectual property.
- The base-case commercial outlook is a mature, Japan-centered niche market.
FAQs
Can camostat be prescribed for COVID-19 in the United States?
Camostat is not an FDA-approved COVID-19 treatment. Its use in the United States would generally require an applicable clinical-trial or other authorized pathway.
Is camostat a protease inhibitor like nirmatrelvir?
Camostat inhibits host serine proteases such as TMPRSS2 and trypsin. Nirmatrelvir directly inhibits the SARS-CoV-2 main protease, Mpro. The mechanisms and clinical evidence are different.
Does camostat have biosimilar competition?
No. Camostat is a synthetic small molecule, not a biologic. Competition would arise from generic or reformulated products rather than biosimilars.
Could camostat qualify for orphan-drug exclusivity?
It could qualify only if a sponsor develops it for a disease meeting the applicable orphan-drug criteria and obtains designation and approval. Existing Japanese approval does not itself create U.S. orphan exclusivity.
Is camostat commercially attractive for pharmaceutical licensing?
The legacy oral product has limited licensing attractiveness because of old chemistry, weak exclusivity, and unsuccessful COVID-19 development. A proprietary inhaled formulation or clinically validated new indication would materially improve the licensing case.
References
-
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Muller, M. A., Drosten, C., & Pohlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271-280.e8.
-
Gunst, J. D., Mygind, L. H., Brouwer, M. C., et al. (2021). Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19: A double-blind randomized controlled trial. eClinicalMedicine, 35, 100849.
-
National Institutes of Health. (2023). ACTIV-2/A5401: A study of investigational drugs for the treatment of COVID-19 in outpatients. ClinicalTrials.gov.
-
PRINCIPLE Trial Collaborative Group. (2022). Effect of oral camostat mesilate on time to sustained recovery in non-hospitalized adults with COVID-19: The PRINCIPLE randomized clinical trial. The Lancet Respiratory Medicine.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
Ono Pharmaceutical Co., Ltd. (2024). Product information for Foipan tablets and camostat mesilate. Japan.